Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases

Intractable and Rare Diseases Research

Volumn 3, Issue 4, 2014, Pages 162-165

  Zukhrofi, Muzar ^a   Adams, Patrick E ^a,b   Andrea, Schneider ^a,b   Hagerman, Randi J ^a,b   Reymundo, Lozano ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FXTAS; neurological deterioration; opiates; premutation; Substance abuse

Indexed keywords

EID: 85010089463     PISSN: 21863644     EISSN: 2186361x     Source Type: Journal    
DOI: 10.5582/irdr.2014.01023     Document Type: Article

References (30)

1. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 2004; 291:460-469.
2. Li Y, Jin P. RNA-mediated neurodegeneration in fragile X-associated tremor/ataxia syndrome. Brain Res. 2012; 1462:112-117.
3. Berry-Kravis E, Hall D, Leehey M, Hagerman R. Treatment and management of FXTAS. In: Tassone F, Berry-Kravis E, eds. The fragile X-associated tremor ataxia syndrome (FXTAS). New York: Springer, 2011: 137-154.
4. Leehey M, Hagerman P. Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Subramoney SH, Durr A, editors. Ataxic Disorders 1: Handbook of Clinical Neurology, 3rd Series. Edinburgh, Scotland: Elsevier; In press.
5. Leehey M, Legg W, Tassone F, Hagerman R. Fibromyalgia in fragile X mental retardation 1 gene premutation carriers. Rheumatology (Oxford). 2011; 50:2233-2236.
6. Winarni TI, Chonchaiya W, Sumekar TA, Ashwood P, Morales GM, Tassone F, Nguyen DV, Faradz SM, Van de Water J, Cook K, Hamlin A, Mu Y, Hagerman PJ, Hagerman R.J. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A. 2012; 158A:2473-2481.
7. Coffey SM, Cook K, Tartaglia N, Tassone F, Nguyen DV, Pan R, Bronsky HE, Yuhas J, Borodyanskaya M, Grigsby J, Doerflinger M, Hagerman PJ, Hagerman R.J. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146A:1009-1016.
8. Au J, Akins RS, Berkowitz-Sutherland L, Tang HT, Chen Y, Boyd A, Tassone F, Nguyen DV, Hagerman R. Prevalence and risk of migraine headaches in adult fragile X premutation carriers. Clin Genet. 2013; 84:546-551.
9. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol. 2013; 12:786-798
10. Kogan CS, Turk J, Hagerman RJ, Cornish KM. Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: A controlled study. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B:859-872.
11. Kumar V, Abbas AK, Fausto N, ed. Robbins and Cotrans. Pathological basis of disease (7th ed.). Elsevier/Saunders 2005; 911-2. ISBN 0-7216-0187-1
12. Fletcher LM, Powell LW. Hemochromatosis and alcoholic liver disease. Alcohol (Fayetteville, NY). 2003; 30:131-136.
13. Farzin F, Perry H, Hessl D, Loesch D, Cohen J, Bacalman S, Gane L, Tassone F, Hagerman P, Hagerman R. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006; 27:137-144.
14. Chonchaiya W, Au J, Schneider A, Hessl D, Harris SW, Laird M, Mu Y, Tassone F, Nguyen DV, Hagerman RJ. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet. 2012; 131:581-589.
15. Tassone F, Hagerman RJ, Taylor AK, Mills JB, Harris SW, Gane LW, Hagerman PJ. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet. 2000; 91:144-152.
16. Aziz M, Stathopulu E, Callias M, Taylor C, Turk J, Oostra B, Willemsen R, Patton M. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet. 2003; 121B:119-127.
17. Hessl D, Wang JM, Schneider A, Koldewyn K, Le L, Iwahashi C, Cheung K, Tassone F, Hagerman PJ, Rivera SM. Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biol Psychiatry. 2011; 70:859-865.
18. Seritan A, Ortigas M, Seritan S, A. Bourgeois J, J. Hagerman R. Psychiatric disorders associated with FXTAS. Curr Psychiatr Rev. 2013; 9:59-64.
19. Bacalman S, Farzin F, Bourgeois JA, Cogswell J, Goodlin-Jones BL, Gane LW, Grigsby J, Leehey MA, Tassone F, Hagerman R.J. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: Newly described fronto-subcortical dementia. J Clin Psychiatry. 2006; 67:87-94.
20. Tassone F, Greco CM, Hunsaker MR, Seritan AL, Berman RF, Gane LW, Jacquemont S, Basuta K, Jin LW, Hagerman PJ, Hagerman RJ. Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav. 2012; 11:577-585.
21. Zhang L, Coffey S, Lua LL, Greco CM, Schafer JA, Brunberg J, Borodyanskaya M, Agius MA, Apperson M, Leehey M, Tartaglia N, Tassone F, Hagerman PJ, Hagerman R.J. FMR1 premutation in females diagnosed with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009; 80:812-814.
22. Greco CM, Tassone F, Garcia-Arocena D, Tartaglia N, Coffey SM, Vartanian TK, Brunberg JA, Hagerman PJ, Hagerman RJ. Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis. Arch Neurol. 2008; 65:1114-1116.
23. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, Xunclà M, Badenas C, Kulisevsky J, Gomez B, Milà M. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet. 2009; 17:1359-1362.
24. Lozano R, Hagerman RJ, Duyzend M, Budimirovic DB, Eichler EE, Tassone F. Genomic studies in fragile X premutation carriers. J Neurodev Disord. 2014; 6:27.
25. Leehey MA, Berry-Kravis E, Min SJ et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord. 2007; 22:203-206.
26. Chen Y, Tassone F, Berman RF, Hagerman PJ, Hagerman RJ, Willemsen R, Pessah IN. Murine hippocampal neurons expressing FMR1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet. 2010; 19:196-208.
27. Bora E, Yucel M, Fornito A, Pantelis C, Harrison BJ, Cocchi L, Pell G, Lubman DI. White matter microstructure in opiate addiction. Addict Biol. 2012; 17:141-148.
28. Arnone D, Barrick TR, Chengappa S, Mackay CE, Clark CA, Abou-Saleh MT. Corpus callosum damage in heavy marijuana use: Preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuromage. 2008; 41:1067-1074.
29. Bhadelia RA, Price LL, Tedesco KL, Scott T, Qiu WQ, Patz S, Folstein M, Rosenberg I, Caplan LR, Bergethon P. Diffusion tensor imaging, white matter lesions, the corpus callosum, and gait in the elderly. Stroke. 2009; 40:3816-3820.
30. Apartis E, Blancher A, Meissner WG, et al. FXTAS: New insights and the need for revised diagnostic criteria. Neurology. 2012; 79:1898-1907.